<DOC>
	<DOCNO>NCT00719316</DOCNO>
	<brief_summary>The central hypothesis project Aliskiren cause substantial decrease MSNA hypertensive patient CKD .</brief_summary>
	<brief_title>Aliskiren Muscle Sympathetic Nerve Activity</brief_title>
	<detailed_description>Cardiovascular ( CV ) morbidity mortality frequently occur problem chronic kidney disease ( CKD ) patient . Apart call traditional risk factor , also risk factor less specific CKD contribute pathogenesis problem . There strong evidence sympathetic hyperactivity , often characterize CKD , one factor . Previously , show angiotensin convert enzyme inhibitor ( ACEi ) angiotensin II receptor blocker ( ARB ) reduce normalize sympathetic hyperactivity . We re-analysed cohort patient investigate past subsequently treat accord present guideline . The result show , despite treatment , unfavourable relation sympathetic hyperactivity clinical outcome still exit . This might mean treatment insufficient . In present study , want study effect Aliskiren 300mg sympathetic nerve activity .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Patients stable chronic kidney disease hypertension : i.e . use antihypertensive drug and/or blood pressure &gt; 145/90 mmHg medication . Patients ACE inhibitor ARB Patients diabetes mellitus Patients renal replacement therapy Pregnant patient Using antihypertensive stop Patients immunosuppressive therapy active nephrotic syndrome</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Renin inhibitor</keyword>
	<keyword>Patients</keyword>
	<keyword>ACE inhibitor ARB</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Hypertension</keyword>
</DOC>